Excellent local disease control (DCR) of 100% at Week 8 and 87% (Week 16)
Substantial tumour volumetric reductions up to 72% @ Week 16 (median volume reduction 39.5%)
Potentially 6/20 patients going to resection (30%) – 2 already with clear margins.
Let’s look for some comparative data – Celgene published data at the 2018 ASCO GI meeting earlier this year (January) on the combination of ABRAXANE + gemcitabine chemotherapy (the same chemo being used with OSL)
DCR at Week 16 was 77% cf OSL at 87% - clearly OSL has an added effect!
Resection rate was only 15% - OSL + Chemo is potentially headed to 30% - lets see – early days
OSL + chemo has the potential to achieve disease control better than chemo alone, leading to opportunities for additional treatment interventions – This is strong evidence thus far for the need to add OSL to Chemo.
No evidence of negative interactions between OSL and chemo - No SAEs related to device, no evidence of radiation toxicities. Side effect profile is excellent
OSL Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)